My ePortfolio Register   

AACR 2014 /
Promising research on the use of palbociclib in the treatment of breast cancer

5th - 9th Apr 2014

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 01.05.14
Views: 1806

Dr Richard Finn - Ronald Reagan UCLA Medical Center, Los Angeles, USA

At a press conference during the AACR conference, Dr Finn discussed the results of a randomized Phase II study of PD 0332991, a cyclin-dependent kinase (CDK)-4/6 inhibitor, in combination with letrozole vs letrozole alone for first-line treatment of ER /HER2- advanced breast cancer (PALOMA-1; TRIO-18).

His research finds that PD 0332991, now known as palbociclib, holds new promise in the treatment of breast cancer.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence